blinatumomab
amgen,astellas
['leukemia', 'blinatumomab', 'leusm']
#ash22 #leusm litzow: n=488 on e1910, primary objective os w/wo blin. 286 randomized (224 mrd neg, 62 mrd+). mrd assessed by flow with cutoff 0.01%. median age 51. cr/cri 81%. median followup 43mos. 80% recd 2+ cycles blin. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)